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Inhibitors of serine peptidases (ISPs) expressed by Leishmania major enhance intracellular parasitism in macrophages by targeting
neutrophil elastase (NE), a serine protease that couples phagocytosis to the prooxidative TLR
4
/PKR pathway. Here we investigated
the functional interplay between ISP-expressing L. major and the kallikrein-kinin system (KKS). Enzymatic assays showed that NE
inhibitor or recombinant ISP-2 inhibited KKS activation in human plasma activated by dextran sulfate. Intravital microscopy in the
hamster cheek pouch showed that topically applied L. major promastigotes (WT and Δ𝑖𝑠𝑝2/3 mutants) potently induced plasma
leakage through the activation of bradykininB
2
receptors (B
2
R).Next, usingmAbs against kininogen domains, we showed that these
BK-precursor proteins are sequestered by L. major promastigotes, being expressed at higher % in the Δ𝑖𝑠𝑝2/3mutant population.
Strikingly, analysis of the role of kinin pathway in the phagocytic uptake of L.major revealed that antagonists of B
2
R or B
1
R reversed
the upregulated uptake of Δ𝑖𝑠𝑝2/3mutants without inhibiting macrophage internalization ofWT L. major. Collectively, our results
suggest that L. major ISP-2 fine-tunes macrophage phagocytosis by inhibiting the pericellular release of proinflammatory kinins
from surface boundkininogens.Ongoing studies should clarifywhetherL.major ISP-2 subverts TLR
4
/PKR-dependent prooxidative
responses of macrophages by preventing activation of G-protein coupled B
2
R/B
1
R.
1. Introduction
Integrated by 3 serine proteases, factor XII (FXII), factor XI
(FXI), and plasma prekallikrein (PK) and by one nonen-
zymatic cofactor, high molecular weight kininogen (HK),
the kallikrein-kinin system (KKS), also referred to as the
plasma contact pathway of coagulation, is assembled and
activated when the blood comes in contact with negatively
charged polymers of endogenous origin ormicrobial surfaces
[1, 2]. Upon binding to these negatively charged structures,
the zymogen FXII undergoes a conformational change that
endows the unstable proenzyme with limited enzymatic
activity. Activated FXII (FXIIa) then cleaves prekallikrein
(complexed to the cofactor HK), generating PKa. Reciprocal
cleavage reactions between FXIIa and PKa amplify the prote-
olytic cascade, leading to downstream (i) generation of fibrin
via the FXIIa/FXIa-dependent procoagulative pathway, (ii)
release of the internal bradykinin (BK) moiety of HK by PKa.
Once liberated, the short-lived BK induces vasodilation and
increases microvascular permeability through the activation
of bradykinin B
2
receptors (B
2
R) expressed in the endothe-
lium lining [1]. In addition, themultifunctional PKa generates
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plasmin, an effector of fibrinolysis, and cleaves native C3 of
the complement system C3 [3, 4].
Although HK is classically regarded as the parental
precursor of proinflammatory kinins, the cleaved form of HK
(HKa), a disulfide linked two-chain structure, has additional
biological functions. For example, it has been reported that
HKa reduces neutrophil adhesive functions upon binding to
𝛽2-integrin Mac-1 (CR3, CD11b/CD18, 𝛼M𝛽2) [1, 5]. More
recently, Yang et al. [6] appointed HK/HKa as the plasma-
borne opsonins that drive efferocytosis of apoptotic cells via
plasminogen activator receptor (uPAR)/RAC1-pathway. After
binding to phosphatidyl serine (PS) exposed by apoptotic
neutrophils, the surface-bound HK binds to uPAR before
switching off proinflammatory responses ofmacrophages [6].
In contrast to this novel immunoregulatory function, HK
(and low molecular weight kininogen, LK) are traditionally
viewed as precursors of proinflammatory kinins. Once leaked
into extravascular tissues, the plasma-borne HK/LK undergo
proteolytic cleavage by tissue kallikrein, releasing the B
2
R
agonist lysyl-BK (LBK) in inflammatory exudates [1]. It is
noteworthy that oxidized forms of kininogens may release
bioactive kinins as result of cooperation between neutrophil
elastase (NE) andmast cell tryptase [7, 8]. Acting as paracrine
hormones, the short-lived kinins (BK or LBK) swiftly acti-
vate G-protein coupled bradykinin B
2
receptors (B
2
R), a
subtype of receptor constitutively expressed by endothelial
cells, nociceptive neurons, macrophages, and DCs [1, 9–
11]. The long-range signaling activity of intact kinins is
controlled by kinin-degrading metallopeptidases, such as
the angiotensin converting enzyme (ACE/kininase II) [1].
In addition, the liberated kinin peptides are metabolized
by kininase I (carboxypeptidase N or M); removal of the
C-terminal Arg residue generates des-Arg-kinins, the high-
affinity ligands of B
1
R, a GPCR subtype whose expression is
strongly upregulated in injured/inflamed tissues [12].
During the last decade, research conducted in our
laboratory showed that kinins proteolytically released in
peripheral sites of T. cruzi or Leishmania chagasi infection
reversibly couple inflammation to antiparasite immunity [13–
17]. Another interesting twist came from studies showing
that activation of the contact system/KKS promotes bacterial
entrapment within fibrin meshes, thus providing a physical
barrier against the systemic spread of microbial pathogens
[18]. To this date, however, it is unclear whether the contact
pathway modulates immunity at early stages of cutaneous
leishmaniasis. Intravital microscopy studies conducted in the
mouse ear model of L. major infection [19–21] have shown
that infiltrating neutrophils engulf the promastigotes before
expressing the apoptotic markers required for efferocytosis
by dermal DCs. After internalizing the parasitized/apoptotic
neutrophils, the dermal DCs are no longer capable of steering
protective TH1-responses in the draining lymph node [19–
21]. Although efferocytosis has strong impact onDC function
and TH development in L. major infection, independent
studies showed that macrophage clearance of apoptotic
neutrophils may either induce pro- or anti-inflammatory
responses in NE-dependent manner, the intracellular fate of
the parasite being influenced by the host genetic background
[22, 23].
In natural infection by blood-feeding arthropods, insect
proboscis inevitably causes bleeding, which then causes
the mixing of plasma and sandfly saliva substances with
parasites deposited in the injured dermis [24]. Interestingly,
Phlebotomy duboscq, a vector of Leishmania species, con-
tains high levels of a salivary protein (PdSP15) that inhibits
the contact pathway [25] by binding to negatively charged
polymers of endogenous origin—such as platelet-derived
polyphosphates [2, 18, 26]. Considering that activation of the
procoagulative contact system inducesmicrovascular leakage
through PKa-mediated release of BK, it is conceivable that
sandfly-transmitted Leishmania promastigotes have evolved
the means to subvert the innate effector function of the kinin
pathway at early stages of infection.
The current study was motivated by the recent discov-
ery that Leishmania has three genes encoding ecotin-like
inhibitors of serine peptidases (ISPs) [27]. Previous studies
with the archetype of the family Escherichia coli ecotin [28]
showed that this inhibitor targets neutrophil elastase (NE)
[29]—a member of the trypsin-fold serine peptidases of clan
PA/family S
1A. After noting that the Leishmania genome [30]
lacks these endogenous serine peptidase targets, Eschenlauer
et al. [27] predicted that L. major ISPs might target S
1A-
family serine peptidases expressed by cells of the innate
immune system, such as NE, tryptase, and cathepsin G [30].
In a series of elegant studies, Eschenlauer et al. [27] and
Faria et al. [31, 32] addressed this issue using L. major lines
lacking ISP2 and ISP3 (Δ𝑖𝑠𝑝2/3). After studying the outcome
of interactions between L. major promastigotes and elicited
macrophages, these authors found that these phagocytes
internalized the Δ𝑖𝑠𝑝2/3 promastigotes far more efficiently
than ISP-expressing wild-type (WT) parasites [27, 31] and
linked the upregulated CR3-dependent phagocytosis of the
Δ𝑖𝑠𝑝2/3 L. major mutants to NE-dependent activation of
innate immunity via the TLR
4
/PKR/TNF-𝛼/IFN-𝛽, a proox-
idative pathway that limits intracellular parasite survival
[31, 32]. Notably, the phenotype of Δ𝑖𝑠𝑝2/3 promastigotes
was reversed by supplementing the macrophage cultures
with purified (recombinant) ISP-2 or with the synthetic
NE inhibitor (MeOSuc-AAPV-CMK), at the onset of infec-
tion [31]. Based on these collective findings, these authors
suggested that ISP-2 expressing L. major promastigotes
might downmodulate phagocytosis and limit microbicidal
responses of macrophages by preventing NE-dependent acti-
vation of TLR
4
[31, 32]. More recently, we have documented
that macrophages internalize and limit intracellular T. cruzi
growth in residentmacrophages through activation pathways
forged by the cross-talk between bradykinin B
2
receptors and
C5a receptors [33]. Intrigued by the similarities that exist
between the phenotype of the L. major Δ𝑖𝑠𝑝2/3 mutant and
L. chagasi promastigotes [15] and T. cruzi trypomastigotes
(Dm28 strain) [33, 34], in the current work we interrogated
whether ISP-expressing L. major and the ISP-2 Δ𝑖𝑠𝑝2/3
mutants differ in their ability to activate the KKS in vivo and
in vitro. Using intravital microscopy, we first showed that L.
major promastigotes topically applied to the hamster cheek
pouch potently activate the KKS extravascularly, irrespective
of presence/absence of ISP. In the second part of this study,
we present evidence indicating that ISP-expressing L. major
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may subvert innate immunity by targeting kinin-releasing
serine proteases (S
1A family) exposed at the cell-surface of
macrophages.
2. Materials and Methods
2.1. Parasites. L. major Promastigotes of Friedlin (MHOM/
JL/80/Friedlin) were grown in modified Eagle’s medium
(HOMEM, Sigma) supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Gibco) at 25∘C, as previously
described [31, 32]. Suspensions of promastigotes were washed
twice with PBS before being used either in vitro or in
vivo. Leishmania major deficient in ISP2 and ISP3 (Δ𝑖𝑠𝑝2/3)
were generated as previously described by Eschenlauer
et al. [27]. The following antibiotics were used at the
indicated concentration for the selection of transfectants:
50mg/mL hygromycin B (Roche), 25mg/mL G418 (Invit-
rogen), 10mg/mL phleomycin (InvivoGen), and 50mg/mL
puromycin dihydrochloride (Calbiochem).
2.2. Intravital Digital Microscopy. Syrian hamsters, 3-month-
old males, were maintained and anesthetized according to
regulations given by the local ethical committee (IBCCF,
protocol-014, 23/02/2008). Altogether 65 hamsters (114 ±
18 g) (Anilab, Sa˜o Paulo, Brazil) were used. Anesthesia was
induced by intraperitoneal injection of sodium pentobarbital
3% that was supplemented with i.v. 𝛼-chloralose (2.5% W/V,
solution in saline) through a femoral vein catheter. A tracheal
cannula (PE 190) was inserted to facilitate spontaneous
breathing and the body temperature was maintained at 37∘C
by a heating pad monitored with a rectal thermistor. The
hamster cheek pouch (HCP) was prepared and used for
intravital microscopy as previously reported [34, 35]. The
microcirculation of theHCPwas observed using anAxioskop
40 microscope, objective 4x, and oculars 10x equipped with
a LED light source Colibri (Carl Zeiss, Germany) and
appropriate filters (490/520 nm and 540/580 nm, rhodamine)
for observations of fluorescence in epiluminescence. A digital
camera, AxioCamHRc, and a computer with the AxioVision
4.4 software program (Carl Zeiss, Germany) were used for
image analysis of arteriolar diameter and total fluorescence
in a representative rectangular area (5mm2) of the pre-
pared HCP. Fluorescence was recorded for 30min prior to
experimental interventions to secure normal blood flow and
unaltered vascular permeability and the fluorescence mea-
sured at 30min after FITC-dextran (FITC-dextran 150 kDa,
100mg/kg bodyweight, TdB Consultancy, Uppsala, Sweden)
injection was adjusted to 2000 fluorescent units (RFU =
Relative Fluorescent Units) for statistical reasons. Leukocytes
were labeled in vivo by injecting rhodamine 100 𝜇g/kg b.w i.v.
(10min prior to experimental interventions), reinforced by
injection of the same tracer at 10 𝜇g/kg b.w. every 10min until
60min.The recorded fluorescence at 10min after rhodamine
injection in each experiment was adjusted to 3000 fluorescent
units (RFU) for statistical reasons. Two images of exactly the
same area were recorded at every 5min interval during the
entire experiment. One was used to measure plasma leakage
and arteriolar diameter (490/520 nm) and the other to mea-
sure total fluorescence of rhodamine-labeled leukocytes in
circulation, rolling, adherence, and migration (540/580 nm)
in the observed area (5mm2) here defined as leukocyte
accumulation. Exposure time was limited to 15 s for each
captured image in order to avoid phototoxicity. Following
30min control period after FITC-dextran injection HCPs
were topically exposed to WT L. major promastigotes or
Δ𝑖𝑠𝑝2/3 (7.5 × 106/500 𝜇L) during interruption of the super-
fusion for 10min. Cromoglycate was injected i.p. (40mg/kg
b.w.) at time of pentobarbital anesthesia and dextran sulfate
500 kDa (TdB Consultancy, Uppsala, Sweden) was injected
i.v. (2mg/kg) prior to parasite application. HOE-140 tested at
0.5 𝜇M and the histamine receptor H1 mepyramine (10 𝜇M)
were applied locally via a syringe pump into the superfusion
during 10min prior to application of promastigotes.
2.3. Isolation of Peritoneal Macrophages and Invasion Assays.
C57BL/6 mice received an intraperitoneal injection of 2mL
of 3% thioglycolate and macrophages were harvested from
peritoneal lavage 3 days later. Macrophages were plated on
13 mm coverslips in 24-well plate and after 20 h of incubation
at 37∘C in complete medium (RPMI + 10% FBS, 100U/mL
penicillin, and 100 𝜇g/mL streptomycin) the nonadherent
cells were removed by washing the monolayer of cells with
PBS. Invasion assays were performed by adding stationary
phase promastigotes to the monolayers at a ratio of 5 : 1
(parasite/macrophage) in medium containing 1mg/mL albu-
min from bovine serum (BSA, Sigma). The interaction was
performed during 3 h in a humidified chamber containing
5% CO
2
at 37∘C. When indicated, the culture medium
was supplemented with 100 nM of B
2
R antagonist (HOE-
140, Sigma) or 1 𝜇M of B
1
R antagonist des-Arg9-[Leu8]-BK
(DAL8-BK; Sigma), 5 minutes before addition of parasites.
After interaction, extracellular promastigotes were removed
by washing the monolayers twice with PBS, which were then
fixedwith Bouin overnight and stainedwithGiemsa (Merck).
The number of intracellular amastigotes was determined
by counting at least 100 cells per replicate under the light
microscope. All assays were done in triplicates and results
were expressed as mean values ± SD.
2.4. Parasite Surface Staining. Promastigotes were preincu-
bated with PBS-1% BSA for 1 hour to avoid unspecific
binding and then incubated for 1 h with monoclonal anti-
body MBK
3
(IgG1—1 : 50) or HKH4 (IgG
2a—1 : 50), kindly
provided by Dr. W. Mu¨ller-Esterl from Frankfurt University.
MBK
3
recognizes the BK epitope in domain D4 of human
and bovine H-/L-kininogens whereas HKH
4
binds to the D1
domain [36]. Isotype-matched monoclonal antibodies were
used as negative controls. Parasites were washed three times
with PBS-1% BSA and incubated with secondary fluorescent
antibody (FITC—1 : 50) for 30min at 4∘C, protected from
light. After washing, the samples were acquired by flow
cytometry (FACSCan; BD Biosciences), and data analyses
were done with Summit software (Dako Colorado, Inc).
Assays were done in duplicates and results are representative
of two independent experiments.
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2.5. Contact Phase Activation of Human Plasma. The acti-
vation of FXII/PK in human citrated (platelet free) plasma
treated (or not) with dextran sulfate (DXS; 500 kDa, TdB
Consultancy) was monitored by spectrofluorimetry as pre-
viously described [37], using internally quenched fluo-
rescent substrates whose sequences correspond to the
C-terminal (Abz-GFSPFRSVTVQ-EDDnp) or N-terminal
flanking region (Abz-MTEMARRPQ-EDDnp m) of BK of
mouse kininogen. The hydrolysis of the cleaved substrate
Abz-peptidyl-EDDnp (Abz = o-aminobenzoyl and EDDnp =
ethylenediamine 2,4-dinitrophenyl) was monitored by mea-
suring the fluorescence at 𝜆ex. = 320 nm and 𝜆em. = 420 nm
in a Spectramax M5 fluorescence spectrophotometer. The
reaction was carried out in PBS, pH 7.4, using citrated human
plasma 1 : 20, 4 𝜇M of the Abz-peptidyl-EDDnp substrate
and 20 nM of the contact system activator DXS (500 kDa).
As internal controls, the plasma was pretreated with the
synthetic PKa inhibitor (PKSI-527—5𝜇M) [38]. Assays with
recombinant ISP-2 (kindly supplied by A. P. C. A. Lima)
were performed at final concentrations of 142, 177, 240, and
355 nM; the neutrophil elastase (NE) inhibitor MeOSuc-
AAPV-CMK (Calbiochem) was tested at 10, 20, and 30𝜇M.
PKSI or recombinant ISP2 and MeOSuc-AAPV-CMK were
preincubated with human plasma for 15min, at 37∘C, prior to
the addition of DXS and the substrate. Plasma was prepared
by centrifugation of blood samples at 2500 g for 20min at
4∘C. After centrifugation, plasma samples were filtered using
a 0.2 𝜇mmembrane.
2.6. Statistical Analyses. Statistical analyses were done using
PRISM 5.0 (GraphPad Software). Comparisons of the means
of the different groups were done by one-way analysis of
variance (ANOVA). When the mean values of the groups
showed a significant difference, pairwise comparison was
performed with the Tukey test. A 𝑃 value of 0.05 or less was
considered to indicate a statistically significant difference. For
intravital experiments, we used ANOVA or pairwise t-test,
when appropriate.
3. Results
3.1. Analysis of theDynamics of Inflammation inHCPTopically
Sensitized with L. major Promastigotes. Intravitalmicroscopy
in HCP has provided a wealth of information about the inter-
play between the KKS and the topically applied pathogens
because this method dispenses the use of needles, thus
ruling out the influence of bleeding and collateral activation
of the contact system in the analysis of microcirculatory
parameters. As a starting point in thiswork,we askedwhether
the proinflammatory responses evoked by ISP-expressing L.
major promastigotes or ISP-deficient parasites were com-
parable. Our results (Figures 1–3) revealed that L. major
(WT) promastigotes induced a very robust and reversible
microvascular leakage that was detectable at 20min and
reached its maximal value 45min after pathogen application
(Figures 1(a)–1(c)). In 4 out of 15 experiments we mea-
sured leukocyte accumulation in and around postcapillary
venules and noted that these circulating cells were promptly
mobilized locally, the response being detectable up to 90min
after pathogen application (Figure 1(b)).The temporal course
and dynamics of the plasma leakage response evoked by
WT promastigotes were quite different from the classical
responses elicited by BK, histamine, or leukotrienes, all of
which cause amaximal increasewithin 10min and reversed to
steady-state conditions within 30min [39, 40]. Intriguingly,
we found that the leakage responses evoked by L. major
(WT) promastigotes were generally more robust than those
induced by the same inoculum of L. donovani promastigotes
(Figure 1(c)) [16] or T. cruzi (tissue culture trypomastigotes,
Dm28c strain) [35]. Akin to the findings made in the above-
mentioned studies, we found that topically applied HOE-140
(B
2
R antagonist) markedly reduced L. major (WT-) induced
plasma leakage (Figure 1(a)).
Considering that mast cells are innate sentinel cells
strategically localized in the perivascular tissues, we next
interrogated whether L. major promastigotes might evoke
plasma leakage in mast cell-dependent manner. As shown in
Figure 1(a), the topical addition of mepyramine (histamine-
1-receptor blocker) markedly inhibited the macromolecular
leakage induced by L. major promastigotes. In a limited
series of studies, we found that cromoglycate, a well-known
mast cell stabilizer, abolished the L. major-induced leakage
of plasma (Figure 1(b), lower panel). Of further interest, cro-
moglycate prevented leukocyte accumulation in the parasite-
laden microvascular beds, reducing this parameter to levels
below controls (Figure 1(b), top panel). It is noteworthy that
the doses of mepyramine and HOE-140 that were topically
added to the HCP at the onset of infection were sufficient
to block the leakage induced by standard solutions of his-
tamine (4 𝜇M) and BK (0.5 𝜇M) [35]. Further expanding
this investigation, we next explored the possibility that the
microvascular leakage elicited by L. major promastigotes
requires the participation of circulating neutrophils. To this
end, we injected separate group of hamsters intravenously
withDXS, a negatively charged polymer (500 kDa) and found
that it profoundly inhibited plasma leakage induced by L.
major promastigotes. Although DXS was initially thought
to inhibit neutrophil-dependent microvascular permeability
by blocking endothelial interaction with neutrophil-derived
cationic proteins [41–44], there is now awareness that these
effects might result from DXS-mediated activation of the
KKS, a systemic reaction that leads to hypotension as result
of excessive BK formation [45].
Finally, we sought to compare themicrovascular respons-
es elicited byWT L. major with their counterparts genetically
deficient in ISP-2/ISP-3. As shown in Figure 1(d), the dynam-
ics of plasma leakage induced by topically applied Δ𝑖𝑠𝑝2/3
mutants was similar to that evoked byWT parasites, the peak
response being observed at 45–50min after pathogen appli-
cation.However, somewhat surprisingly, theΔ𝑖𝑠𝑝2/3mutants
were 20% less effective in eliciting transendothelial leakage of
plasma as compared to WT promastigotes (Figure 1(d)); the
difference in their proinflammatory phenotypes (𝑃 < 0.05)
was already noticeable at 25min after parasite application.
3.2. Bradykinin Receptors Selectively Fuel Macrophage Inter-
nalization of ISP-Deficient L. major. Studies in mice models
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Figure 1: Microvascular plasma leakage and leukocyte accumulation in the HCP sensitized with Leishmania. The data represent relative
fluorescence units (RFU: mean ± SD) induced by the topical application of L. major promastigotes (MHOM/JL/80/Friedlin, 500 𝜇L of 1,5 ×
107/mL) on hamster cheek pouch preparations (HCPs) after 30min of stabilization period without significant increase in RFU. Applications of
promastigotes weremade during 10min of interrupted superfusion of theHCPs. (a) Pharmacological interventions. Four groups of HCPwere
sensitized with L. major WT promastigotes, whereas one group (saline control; 𝑛 = 6) served as untreated control. The first group (𝑛 = 15)
corresponds to the positive controls, that is, profile of HCP exposed to L. major alone; the second group (𝑛 = 5) received HOE-140 (0.5 𝜇M)
5min prior to promastigote application; the third group (𝑛 = 4) received the antagonist of histamine receptor (H1R) mepyramine (10 𝜇M)
5min prior to challenge with promastigotes; and the fourth group (𝑛 = 7) was pretreated (i.v.) with dextran sulfate 500 (DXS-500; 2mg/kg) at
time of FITC-dextran injection. Plasma leakage was significantly reduced (𝑃 < 0.05) in all experimental groups subjected to pharmacological
interventions. (b) Effect of the mast cell stabilizer cromoglycate. Data represent mean values ± SD obtained in HCP sensitized by L. major
WT (𝑛 = 4) and a saline control group (𝑛 = 6). Two hamsters were given cromoglycate 40mg/kg i.p. at time of anesthesia induction, and
this treatment resulted in a complete inhibition of plasma leakage and leukocyte accumulation elicited by L. major despite the fact that the
HCPs responded to histamine stimuli (4 𝜇M) at the end of the experiment, that is, 60min after topical application of L. major promastigotes.
As an internal control, one hamster from the DXS-treated group (𝑛 = 7, Figure 1(a)) received rhodamine i.v. prior to parasite challenge.
Measurements of leukocyte accumulation showed that DXS-500 reduced the Leishmania response to levels below the saline control group
while plasma leakage decreased to the level of controls depicted in Figure 1(a) (data not shown). (c) Comparative analysis of kinin/B
2
R-
driven microvascular plasma leakage induced by different Leishmania species. The graph depicts responses evoked by L. major WT and L.
chagasi promastigotes (500 𝜇L de 1,5 × 107/mL). L. major WT (blue filled circles, 𝑛 = 19); L. chagasi (brown filled circles, 𝑛 = 6); L. chagasi +
captopril 1 𝜇M (black crosses, 𝑛 = 4); L. chagasi + o.5 𝜇M HOE-140 (red squares, 𝑛 = 4); L. chagasi + 10𝜇M mepyramine (orange triangles,
𝑛 = 4); and saline control (grey diamonds, 𝑛 = 3). The maximal microvascular response to L. major was 5-fold higher than L. chagasi at
50min after parasite application. The tests involving pharmacological interventions in HCP sensitized with L. chagasi groups were different
(𝑃 < 0.05) from the L. chagasi control at 40min. (d) Microvascular plasma leakage elicited by L. major Δ𝑖𝑠𝑝2/3. The data represent mean
values ± SD. One group represents the microvascular responses evoked byWT L. major (MHOM/JL/80/Friedlin, 𝑛 = 19) whereas the second
group represents responses induced by L. major Δ𝑖𝑠𝑝2/3 (𝑛 = 16). The plasma leakage induced by WT versus Δ𝑖𝑠𝑝2/3 promastigotes was
significantly different (∗𝑃 < 0.05) between 25 and 60min after topical application of the pathogens.
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Figure 2: Differential role for bradykinin receptors in the phago-
cytic response of macrophages infected by WT L. major pro-
mastigotes and Δ𝑖𝑠𝑝2/3mutants. Thioglycolate elicited (peritoneal)
macrophages were incubated in medium containing 1mg/mL BSA
in the presence or absence of 100 nM of HOE-140 or 1𝜇m of
des-Arg9-[Leu8]-BK (DAL8-BK). Promastigotes were added (para-
site/cell ratio 5 : 1) and incubated for 3 h at 37∘C.White bars represent
L. major WT and black bars represent Δ𝑖𝑠𝑝2/3. Data represent
numbers of intracellular amastigotes per 100 macrophages (means
± SD) for triplicates and represent two different experiments (∗𝑃 <
0.05).
of acute Chagas disease [14] and visceral leishmaniasis
[16] have recently showed that B
2
R-deficient mice exhib-
ited impaired development of type-1 effector T cells, the
immune dysfunction of the transgenic strain being ascribed
to primary deficiency in the maturation of B
2
R−/− DCs
in chagasic mice [14]. In a third study, we examined
the role of the kinin pathway in the in vitro outcome
of macrophage interactions with L. chagasi promastigotes
[15]. Interestingly, these studies revealed that activation of
the kinin/B
2
R pathway may either fuel intracellular par-
asite outgrowth in splenic macrophages from hamsters, a
species that is susceptible to visceral leishmaniasis, or limit
parasite survival in thioglycolate-elicited mouse peritoneal
macrophages [16]. Motivated by this groundwork, in the
next series of experiments we examined the outcome of
macrophage interaction (3 h in the absence of serum) with L.
major promastigotes orΔ𝑖𝑠𝑝2/3mutants. Consistent with the
phenotypic properties of Δ𝑖𝑠𝑝2/3 promastigotes originally
described by Eschenlauer et al. [27], we found that the
phagocytic uptake of these mutants was strongly upregulated
as compared to WT promastigotes (Figure 2). Next, we
asked whether B
2
R (constitutively expressed) or B
1
R (NF𝜅-
B inducible; [35]) contributed to the phagocytic uptake of L.
major. Infection assays performed in the presence of HOE-
140 or DAL8-BK (B
1
R antagonist) revealed that none of
these GPCR antagonists inhibitedmacrophage uptake of ISP-
expressing (WT) L. major. In striking contrast, however, both
GPCR antagonists efficiently reduced the phagocytic uptake
of Δ𝑖𝑠𝑝2/3 promastigotes by the phagocytes (resp., to 58%
and 63%; Figure 2). For reasons that are not clear, the B
1
R
antagonist had a mild but significant stimulatory effect (39%
increase compared with medium) on the uptake of WT L.
major.
3.3. Surface Exposure of the BK Epitope Differs in WT
and Δ𝑖𝑠𝑝2/3 Promastigotes. Since the studies of macrophage
infection by L. major promastigotes were routinely per-
formed in the absence of serum, we reasoned that the kinin
agonists should either originate from kininogens molecules
bound to the surface of macrophages [46] or alterna-
tively from kininogenmolecules eventually sequestered from
serum by promastigotes. To test the latter possibility, we
washed stationary phase L. major promastigotes extensively
as described for infection assays and then stained the para-
sites with two different domain-specific mAbs: (i) MBK
3
, a
monoclonal antibody that recognizes the BK epitope (domain
D
4
) of kininogens (HK/LK), and (ii) HKH
4
, a mAb that
recognizes domain D
1
of HK/LK [36]. FACS analysis showed
that almost 70%ofΔ𝑖𝑠𝑝2/3 promastigotes are positive stained
for HKH4, compared to less than 50% of the WT parasites
(Figure 3(a)). Along similar lines, MBK
3
antibody showed
that the BK epitope of kininogens was present in a higher
proportion of Δ𝑖𝑠𝑝2/3 promastigotes as compared to WT
promastigotes (Figure 3(b), 82,4%) as compared to WT par-
asites (Figure 3(b), 73.1%). These results suggest that both
ISP-expressing L. major promastigotes and Δ𝑖𝑠𝑝2/3 mutants
are able to sequester kininogens (retaining the intact BK
molecule) from FCS. According to our working hypothesis
(Figure 5), the kininogen opsonins tethered on ISP-deficient
parasites may be cleaved by pericellular serine proteases (S
1a
family) of macrophages, whereas the surface-bound kinino-
gens associated to ISP-expressing (WT) L. major should be
protected from proteolytic cleavage.
3.4. Targeting Activation of the Contact Phase/KKS in Human
Plasma with Recombinant ISP-2 or Synthetic Inhibitor of Neu-
trophil Elastase. Considering that ISP-2 is hardly detected in
the supernatants of L. major promastigotes (A. P. C. A. Lima,
personal communication), we reasoned that we reasoned
that this ecotin-like inhibitor may target S
1A serine proteases
within the secluded spaces formed by the juxtaposition of
host cell/parasite plasma membranes. Given the technical
obstacles to monitor KKS activation and kinin release in this
intercellular compartment, we first asked whether soluble
(recombinant) ISP-2 orMeOSuc-AAPV-CMK (NE inhibitor)
could inhibit the activation of the human contact system
by DXS. This was addressed using a novel enzymatic assay
that we recently used to detect the P. duboscq sandfly protein
inhibitor of the contact system [25]. Briefly, the addition
of DXS (500 kDa) to human plasma induces the reciprocal
activation of FXII/PK, leading to the accumulation of PKa,
the major kinin-releasing (S
1A family) in the plasma. Using
as-read-outs synthetic substrates spanning the N-terminal
or C-terminal flanking sequences of BK in the kininogen
molecule, the kinetic measurements shown in our posi-
tive controls (Figure 4) reflect DXS-induced hydrolysis of
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Figure 3: Evidence of differential display of kininogens and BK epitopes on surface of WT L. major versus Δ𝑖𝑠𝑝2/3 promastigotes. WT and
Δ𝑖𝑠𝑝2/3 promastigotes were washed 3x before incubation with mAbs against D1 or D4 (BK epitope) of kininogens, HK/LK (HKH
4
(a) or
MBK
3
(b), resp.) for 1 h. Unrelated Ab (IgG
2a for HKH4 or IgG1 for MBK3 staining) were used as specificity controls. Binding of primary IgG
was assessed by incubating the cells with a secondary FITC-labeled anti-mouse IgG antibody for 1 h. The graphs represent the percentage of
HK/LK adsorption and are representative of two independent experiments performed in duplicates.
the kininogen-like substrate by PKa [25]. Internal controls
run in the presence of the synthetic PKa inhibitor (PKSI-
257) show, as expected, pronounced inhibition of the contact
phase enzyme by DXS. Assays performed with soluble ISP-2
revealed that the onset of hydrolysis was consistently delayed,
in dose-dependent manner (range 142–355 nM; Figures 4(a)
and 4(b)). A similar trend was observed when we added
MeOSuc-AAPV-CMK (NE inhibitor) to the citrated plasma
(range 10–30 𝜇M; Figures 4(c) and 4(d)). Collectively, these
findings are consistent with the proposition that the activity
of the contact phase enzyme complex (FXIIa/PKa) is at least
partially inhibited by ISP-2 (soluble) or by the synthetic NE
inhibitor.
4. Discussion
In the current study, we used genetically modified Δ𝑖𝑠𝑝2/3
mutants of L. major to determine whether these ecotin-
like inhibitors regulate the proinflammatory activity of the
kinin/B
2
R pathway in vivo and in vitro. In the first group
of studies, we demonstrated that L. major promastigotes
potently evoke plasma leakage and induce leukocyte accu-
mulation inmicrovascular beds throughmast cell-dependent
activation of the kinin/B
2
R pathway, irrespective of the
presence or absence of ISP-2. Extending this analysis to
in vitro infection models, we showed that antagonists of
B
2
R (HOE-140) or B
1
R (DAL8-BK) efficiently reversed the
upregulated phagocytic uptake of L. major Δ𝑖𝑠𝑝2/3 by TG-
macrophages without interfering with the internalization of
ISP-expressing (WT) promastigotes. As discussed further
below, these findings suggested that, upon attachment to
the macrophage surface, ISP-expressing promastigotes might
suppress the activation of B
2
R/B
1
R-dependent proinflamma-
tory responses by inhibiting the kinin-releasing activity of
serine proteases (S
1A family).
While studying the functional interplay between NE and
ISP-2 during macrophage infection by Leishmania, Faria
et al. [31, 32] demonstrated that two prominent pheno-
types of Δ𝑖𝑠𝑝2/3 mutants (upregulated phagocytosis and
induction of ROS via the elastase/TLR
4
/PKR pathway) were
completely reversed in cultures supplemented with three
different inhibitors of serine peptidases: aprotinin [27], a non-
specific inhibitor of Arg-hydrolyzers, MeOSuc-AAPV-CMK
(NE inhibitor), and the L.major ISP-2 (soluble/recombinant).
Given the precedent that NE and mast cell tryptase (act-
ing cooperatively) liberate bioactive kinin from oxidized
kininogens [7], our findings that HOE-140 and DAL8-BK
also reversed the phenotype of Δ𝑖𝑠𝑝2/3 mutants suggest
that ISP-expressing L. major might inhibit the pericellular
processing of surface-bound HK through the targeting of
8 Mediators of Inflammation
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Figure 4: Effect of ISP2 onDXS-induced contact phase activation of humanplasma. Citrated humanplatelet free plasma diluted 1 : 20 in buffer
(described in methods) was supplemented with (i) 4𝜇M Abz-MTEMARRPQ-EDDnp (a, c) or 4 𝜇M Abz-GFSPFRSVTVQ-EDDnp (b, d),
intramolecular quenched fluorescent substrates whose sequences span the N-terminal or the C-terminal flanking sites (resp.) of BK in mHK
(ii) dextran sulfate 500 kDa (DXS; 20 nM). The substrate was also tested in the absence of DXS (Control). Assays with the elastase inhibitor
(NEi—MeOSuc-AAPV-CMK-10, 20, and 30 𝜇M), the synthetic PKa inhibitor (PKSI-527—5 𝜇M), and the inhibitor of serine peptidase 2
(ISP2—142, 177, 240, and 355 nM) were performed using two different schemes. (a, b) PKSI or the elastase inhibitor was added to the plasma
together with DXS and the substrate. (c, d) PKSI or ISP2 was preincubated with plasma for 15min, at 37∘C, prior to the addition of DXS and
the substrate. Hydrolysis was followed by measuring the fluorescence at 𝜆ex. = 320 nm and 𝜆em. = 420 nm (up to 1800 seconds). The plot
shows the increase of fluorescence with time, reflecting substrate hydrolysis. The values in the figures represent the mean ± SE of duplicate
determinations performed within 1 representative experiment of 2.
NE. Alternatively, our finding that soluble ISP-2 (or the
NE inhibitor MeOSuc-AAPV-CMK) partially inhibit DXS-
induced activation of the contact system in human citrated
plasma (i.e., PKa-mediated hydrolysis of the flanking sites of
BK in kininogen-like substrates) suggests that ISP-expressing
promastigotes might rely on their surface-associated ISP-2 to
target the contact phase enzymatic complex (FXIIa/PKa/HK)
assembled on macrophage surfaces [46]. Admittedly, genetic
studies will be required to dissect whether ISP-2 subverts
innate immunity by protecting surface kininogens from the
kinin-releasing activity of NE and/or by targeting surface
assembled contact phase peptidases (FXII/PK). Although we
have not systematically analyzed the impact of pharmaco-
logical blockade of B
2
R/B
1
R on the intracellular parasitism
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Figure 5: Scheme shows how ISP-2 limits the kinin-releasing activity of surface S
1
A-proteases of macrophages. As an extension of recently
published studies [27, 31, 32], here we propose that the proinflammatory phenotype of the Δ𝑖𝑠𝑝2/3 mutant (right side of scheme) is due to
increased pericellular release of kininsmediated byNE and/or contact phase serine proteases (FXIIa/PKa). In the absence of ISP-2, the “eatme
signal” of kininogen tethered on L. majormutants might be inactivated by S
1
A-family proteases. In addition, the released kinin peptides fuel
phagocytosis and microbicidal function of macrophages via activation of B
2
R and B
1
R, a subtype of GPCR upregulated in inflamed tissues.
of TG-macrophages, preliminary results suggest that HOE-
140 (tested at 100 nM) upregulates the outgrowth/survival of
Δ𝑖𝑠𝑝2/3mutants inTG-macrophages. If confirmedby genetic
studies, our results may imply that L. major promastigotes
might limit ROS formation via the NE/TLR
4
/PKR/TNF-
𝛼/IFN-𝛽 pathway originally described by Faria et al. [32]
through ISP-2-dependent targeting of kinin-releasing pepti-
dases assembled at the surface of macrophages.
A key event in many inflammatory processes is the
adhesive interaction of circulating neutrophils and activated
endothelial cells in postcapillary venules, a process that is
often coupled to increasedmicrovascular permeability, which
in turn leads to the progressive accumulation of protein-
rich edema fluid in interstitial tissues. Although conceding
that the dynamics of the inflammatory responses that sand-
fly-transmitted Leishmania induces in the injured dermis is
far more complex than what is described in our intravital
microscopy studies, the analysis of microvascular leakage
and leukocyte accumulation in HCP topically sensitized with
L. major promastigotes (WT or ISP2/3-deficient parasites)
revealed that these parasites are far more potent inducers of
plasma leakage and leukocyte accumulation than L. dono-
vani [15], L. chagasi promastigotes (Figure 1(c)), or T. cruzi
trypomastigotes [35]. Although the mechanisms underlying
the discrepant phenotypes of L. major and L. chagasi or T.
cruzi remain unknown, we were intrigued to find out that a
3X-fold higher dose of L. chagasi promastigotes did not evoke
such a strong microvascular response, not even after treating
the HCP with captopril, an inhibitor of kinin degradation
by angiotensin-converting enzyme (Figure 1(c), black curve).
In contrast, T. cruzi and L. chagasi are potentially lethal
pathogens that disseminate systemically and preferentially
target tissue in organs irrigated by fenestrated capillaries.
Under these circumstances, plasma-borne substrates, such
as kininogens, diffuse freely into the visceral tissues invaded
by these visceralizing species of pathogenic trypanosomatids,
both of which were empowered with kinin-releasing cysteine
proteases [15, 47–49]. It is noteworthy that B
2
R-deficient
mice acutely infected by T. cruzi [14] or L. chagasi [16]
display heightened disease susceptibility, implying that the
activation of the kinin/B
2
R pathway may preferentially shift
the host/parasite balance towards protective immunity, at
least during the acute phase.
Since proboscis inevitably provokes some extent of bleed-
ing, we may predict plasma proteins and anti-inflammatory
substances derived from the insect saliva are rapidly mixed
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with metacyclic parasites. Our studies in HCP topically sen-
sitized with L. major promastigotes (which prevents bleeding
and KKS activation due to pathogen inoculation through
needles) suggest that these parasites potently evoke plasma
leakage and leukocyte accumulation in microvascular beds
via the kinin/B
2
R pathway. For reasons that are unclear, we
found thatΔ𝑖𝑠𝑝2/3 promastigotes evoked a somewhat milder
inflammatory response (20%). Incidentally, Eschenlauer et al.
[27] have reported that mice subcutaneously infected with
L. major promastigotes transiently displayed higher tissue
burden of ISP2/ISP-3-deficient parasites as compared to WT
parasites. Lasting 3 days, the parasite burden subsequently
equalized, implying that the selective advantage conferred
to ISP-deficient promastigotes has waned as the infection
progressed.
Based on pharmacological approaches, we showed evi-
dences that L. major activates the KKS via mechanisms
that involve transcellular cross-talk between neutrophils
(intravascularly) and mast cells, a subset of innate sentinel
cells that are mostly localized in perivascular tissues. Beyond
the vasoactive role of histamine, a potent inducer of vascular
permeability, mast cells also release heparin and polyphos-
phates, both of which were recently characterized as endoge-
nous activators of the contact system [50, 51]. Given the inter-
dependent nature of inflammatory circuits, it is likely that
mast cells and the KKS/complement cascades are reciprocally
activated and fueled in the HCP sensitized with L. major
promastigotes. Although we have not studied the impact of
the influx of complement into peripheral sites of L. major
infection, it is well-documented that Leishmania lipophos-
phoglycan is opsonized by C3bi [52]. In the absence of other
potent inflammatory cues, the engagement of macrophage
CR3 by ISP-expressing L. major (WT) promastigotes may
drive phagocytosis without necessarily stimulating the pro-
duction of reactive oxygen intermediates, thereby creating
a hospitable environment for the intracellular growth of L.
major [31, 32]. Although studies in CD11b-deficient BALB/c
mice have recently confirmed that activation of the C3bi/CR3
pathway increases host susceptibility to L. major infection
[53], it will be interesting to know whether CR3-dependent
suppression of IL-12 responses might depend on parasite-
evoked extravasation of complement components to the
extravascular compartment, as proposed here for plasma-
borne kininogens.
Studies in the mouse ear model of sandfly-transmitted
infection showed that L. major metacyclic promastigotes
deposited in the dermis are engulfed by the infiltrating
neutrophils within approximately 3 h [19–21]. Based on the
results described in HCP topically sensitized with L. major
promastigotes, it is conceivable that the proteolytic release of
vasoactive kinins may further stimulate the transendothelial
migration of neutrophils at very early stages of the infection.
Furthermore, given evidence that parasitized neutrophils
expose the apoptotic markers required for efferocytosis, it
will be interesting to know whether plasma leakage may con-
tribute to DC efferocytosis and to the ensuing suppression of
Th1-inductive functions of DCs in the draining lymph nodes
[19–21]. Beyond the impact on adaptive immunity, it is well
established that efferocytosis of apoptotic neutrophils has
profound effect on parasite survival in infected macrophages
[22]. In this context, our finding that kininogen epitopes
(N-terminal D1 and internal/BK/D4 domain) are tethered
at the surface of Leishmania promastigotes is an intriguing
finding because it raises the possibility that ISP-expressing
promastigotes might “protect” the integrity of surface bound
kinin precursors from premature proteolytic degradation by
host proteolytic enzymes. This hypothesis is worth exploring
in light of recent studies showing that HK (an abundant
protein in the bloodstream; 660 nM) binds to PS exposed
on apoptotic neutrophils before stimulating uPAR-dependent
efferocytosis by macrophages via the p130Cas-CrkII-Dock-
180-Rac1 pathway [6]. In other words, ISPs may protect the
integrity of HK opsonins “eat me signals” while at the same
time preventing the liberation of proinflammatory kinins
(see scheme, Figure 5) within sites of parasite attachment
to phagocytes. Although we have not explored the poten-
tial significance of L. major opsonization by kininogens, it
will be interesting to know whetherparasite subsets bearing
the uPAR ligand HK/HKa “eat me signal” might render
macrophage permissive to intracellular survival, perhaps
reminiscent of the apoptotic mimicry paradigm originally
described by Barcinski and coworkers [54].
5. Conclusions
Extending the breadth of our previous investigations about
the role of the kallikrein-kinin system in the immunopatho-
genesis of experimental Chagas disease and visceral leishma-
niasis, the studies reported in this paper suggest that ecotin-
like inhibitors expressed by L. major promastigotes fine-tune
phagocytosis and may limit amastigote survival by inhibiting
the pericellular activity of kinin-releasing serine proteases
(S
1a family) of macrophages.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This study was supported by grants from CNPq/INBEB,
Faperj, and PRONEX. The authors thank Professor Ana
Paula Cabral de Araujo Lima (Instituto de Biof´ısica Carlos
Chagas Filho, Universidade Federal do Rio de Janeiro) for
kindly providing WT and Δ𝑖𝑠𝑝2/3 L. major and inhibitor of
serine peptidase 2 (ISP2) and ProfessorWernerMu¨ller-Esterl
(University of Frankfurt) for donation of anti-kininogen anti-
bodies. They also wish to thank Dr. Marilia Faria (Instituto
de Biof´ısica Carlos Chagas Filho, Universidade Federal do
Rio de Janeiro) for independently testing the B
2
R and B
1
R
antagonists in infection assays with macrophages (unpub-
lished data).
References
[1] A. P. Kaplan and K. Joseph, “Pathogenic mechanisms of
bradykinin mediated diseases: dysregulation of an innate
Mediators of Inflammation 11
inflammatory pathway,” Advances in Immunology, vol. 121, pp.
41–89, 2014.
[2] C. Maas and T. Renne´, “Regulatory mechanisms of the plasma
contact system,” Thrombosis Research, vol. 129, no. 2, pp. S73–
S76, 2012.
[3] U. Amara, M. A. Flierl, D. Rittirsch et al., “Molecular intercom-
munication between the complement and coagulation systems,”
Journal of Immunology, vol. 185, no. 9, pp. 5628–5636, 2010.
[4] D. Ricklin, G. Hajishengallis, K. Yang, and J. D. Lambris,
“Complement: a key system for immune surveillance and
homeostasis,” Nature Immunology, vol. 11, no. 9, pp. 785–797,
2010.
[5] Y. T. Wachtfogel, R. A. deLa Cadena, S. P. Kunapuli et al., “High
molecular weight kininogen binds to Mac-1 on neutrophils by
its heavy chain (domain 3) and its light chain (domain 5),”
Journal of Biological Chemistry, vol. 269, no. 30, pp. 19307–19312,
1994.
[6] A. Yang, J. Dai, Z. Xie et al., “High molecular weight kininogen
binds phosphatidylserine and opsonizes urokinase plasmino-
gen activator receptor-mediated efferocytosis,” The Journal of
Immunology, vol. 192, no. 9, pp. 4398–4408, 2014.
[7] A. Kozik, R. B. Moore, J. Potempa, T. Imamura, M. Rapala-
Kozik, and J. Travis, “A novel mechanism for bradykinin
production at inflammatory sites: Diverse effects of a mixture
of neutrophil elastase and mast cell tryptase versus tissue and
plasma kallikreins on native and oxidized kininogens,” Journal
of Biological Chemistry, vol. 273, no. 50, pp. 33224–33229, 1998.
[8] K. M. Heutinck, I. J. M. ten Berge, C. E. Hack, J. Hamann, and
A. T. Rowshani, “Serine proteases of the human immune system
in health and disease,”Molecular Immunology, vol. 47, no. 11-12,
pp. 1943–1955, 2010.
[9] J. Aliberti, J. P. B. Viola, A. Vieira-de-Abreu, P. T. Bozza, A.
Sher, and J. Scharfstein, “Cutting edge: bradykinin induces IL-
12 production by dendritic cells: a danger signal that drives Th1
polarization,” Journal of Immunology, vol. 170, no. 11, pp. 5349–
5353, 2003.
[10] C. M. Bertram, S. Baltic, N. L. Misso et al., “Expression of kinin
B1 and B2 receptors in immature, monocyte-derived dendritic
cells and bradykinin-mediated increase in intracellular Ca2+
and cell migration,” Journal of Leukocyte Biology, vol. 81, no. 6,
pp. 1445–1454, 2007.
[11] R. Gulliver, S. Baltic, N. L. Misso, C. M. Bertram, P. J.
Thompson, and M. Fogel-Petrovic, “Lys-des[Arg9]-bradykinin
alters migration and production of interleukin-12 in monocyte-
derived dendritic cells,” American Journal of Respiratory Cell
and Molecular Biology, vol. 45, no. 3, pp. 542–549, 2011.
[12] F. Marceau and D. R. Bachvarov, “Kinin receptors,” Clinical
Reviews in Allergy and Immunology, vol. 16, no. 4, pp. 385–401,
1998.
[13] A. C. Monteiro, V. Schmitz, E. Svensjo¨ et al., “Cooperative
activation of TLR2 and bradykinin B2 receptor is required for
induction of type 1 immunity in amousemodel of subcutaneous
infection by Trypanosoma cruzi,” Journal of Immunology, vol.
177, no. 9, pp. 6325–6335, 2006.
[14] A. C. Monteiro, V. Schmitz, A. Morrot et al., “Bradykinin B2
Receptors of dendritic cells, acting as sensors of kinins pro-
teolytically released by Trypanosoma cruzi, are critical for the
development of protective type-1 responses,” PLoS Pathogens,
vol. 3, no. 11, pp. 1730–1744, 2007.
[15] E. Svensjo¨, P. R. Batista, C. I. Brodskyn et al., “Interplay
between parasite cysteine proteases and the host kinin system
modulates microvascular leakage and macrophage infection by
promastigotes of the Leishmania donovani complex,” Microbes
and Infection, vol. 8, no. 1, pp. 206–220, 2006.
[16] D. Nico, D. F. Feijo´, and N. Maran, “Resistance to visceral
leishmaniasis is severely compromised in mice deficient of
bradykinin B2-receptors,” Parasites and Vectors, vol. 5, no. 1,
article 261, 2012.
[17] J. Scharfstein, D. Andrade, E. Svensjo¨, A. C. Oliveira, and C.
R. Nascimento, “The kallikrein-kinin system in experimen-
tal Chagas disease: a paradigm to investigate the impact of
inflammatory edema on GPCR-mediated pathways of host cell
invasion by Trypanosoma cruzi,” Frontiers in Immunology, vol.
3, no. 396, pp. 1–20, 2007.
[18] B. Engelmann and S. Massberg, “Thrombosis as an intravascu-
lar effector of innate immunity,” Nature Reviews Immunology,
vol. 13, no. 1, pp. 34–45, 2013.
[19] N. C. Peters, J. G. Egen, N. Secundino et al., “In vivo imaging
reveals an essential role for neutrophils in leishmaniasis trans-
mitted by sand flies,” Science, vol. 321, no. 5891, pp. 970–974,
2008.
[20] N. C. Peters, “In vivo imaging reveals an essential role for
neutrophils in Leishmaniasis transmitted by sand flies,” Science,
vol. 322, no. 5908, p. 1634, 2008.
[21] F. L. Ribeiro-Gomes, N. C. Peters, A. Debrabant, and D. L.
Sacks, “Efficient capture of infected neutrophils by dendritic
cells in the skin inhibits the early anti-leishmania response,”
PLoS Pathogens, vol. 8, no. 2, Article ID e1002536, 2012.
[22] F. L. Ribeiro-Gomes, M. C. A. Moniz-de-Souza, M. S.
Alexandre-Moreira et al., “Neutrophils activate macrophages
for intracellular killing of Leishmania major through recruit-
ment of TLR4 by neutrophil elastase,”The Journal of Immunol-
ogy, vol. 179, no. 6, pp. 3988–3994, 2007.
[23] A. A. Filardy, D. R. Pires, and G. A. Dosreis, “Macrophages
and neutrophils cooperate in immune responses to Leishmania
infection,” Cellular and Molecular Life Sciences, vol. 68, no. 11,
pp. 1863–1870, 2011.
[24] R. G. Titus and J. M. C. Ribeiro, “The role of vector saliva in
transmission of arthropod-borne disease,” Parasitology Today,
vol. 6, no. 5, pp. 157–160, 1990.
[25] P. H. Alvarenga, X. Xu, F. Oliveira et al., “Novel family of insect
salivary inhibitors blocks contact pathway activation by binding
to polyphosphate, heparin, and dextran sulfate,”Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 33, no. 12, pp. 2759–2770,
2013.
[26] F. Mu¨ller, N. J. Mutch, W. A. Schenk et al., “Platelet polyphos-
phates are proinflammatory and procoagulant mediators in
vivo,” Cell, vol. 139, no. 6, pp. 1143–1156, 2009.
[27] S. C. P. Eschenlauer, M. S. Faria, L. S. Morrison et al., “Influence
of parasite encoded inhibitors of serine peptidases in early
infection of macrophages with Leishmania major,” Cellular
Microbiology, vol. 11, no. 1, pp. 106–120, 2009.
[28] C. H. Chung, H. E. Ives, S. Almeda, and A. L. Goldberg,
“Purification from Escherichia coli of a periplasmic protein that
is a potent inhibitor of pancreatic proteases,” The Journal of
Biological Chemistry, vol. 258, no. 18, pp. 11032–11038, 1983.
[29] C. T. Eggers, I. A. Murray, V. A. Delmar, A. G. Day, and
C. S. Craik, “The periplasmic serine protease inhibitor ecotin
protects bacteria against neutrophil elastase,” The Biochemical
Journal, vol. 379, no. 1, pp. 107–118, 2004.
[30] A. C. Ivens, C. S. Peacock, and E. A. Worthey, “The genome of
the kinetoplastid parasite, Leishmania major,” Science, vol. 309,
no. 5733, pp. 436–442, 2005.
12 Mediators of Inflammation
[31] M. S. Faria, F. C. G. Reis, R. L. Azevedo-Pereira, L. S. Morrison,
J. C. Mottram, and A. P. C. A. Lima, “Leishmania inhibitor
of serine peptidase 2 prevents TLR4 activation by neutrophil
elastase promoting parasite survival in murine macrophages,”
The Journal of Immunology, vol. 186, no. 1, pp. 411–422, 2011.
[32] M. S. Faria, T. C. Calegari-Silva, A. deCarvalho, J. C. Vivarini, U.
G. Lopes, and A. P. Lima, “Role of protein kinase R in the killing
of Leishmania major by macrophages in response to neutrophil
elastase and TLR4 via TNF𝛼 and IFN𝛽,”TheFASEB Journal, vol.
28, no. 7, pp. 3050–3063, 2014.
[33] V. Schmitz, L. N. Almeida, E. Svensjo¨, A. C. Monteiro, J. Ko¨hl,
and J. Scharfstein, “C5a and bradykinin receptor cross-talk
regulates innate and adaptive immunity in Trypanosoma cruzi
infection,”The Journal of Immunology. In press.
[34] V. Schmitz, E. Svensjo¨, R. R. Serra, M. M. Teixeira, and J.
Scharfstein, “Proteolytic generation of kinins in tissues infected
by Trypanosoma cruzi depends on CXC chemokine secretion
by macrophages activated via Toll-like 2 receptors,” Journal of
Leukocyte Biology, vol. 85, no. 6, pp. 1005–1014, 2009.
[35] D. Andrade, R. Serra, E. Svensjo¨ et al., “Trypanosoma cruzi
invades host cells through the activation of endothelin and
bradykinin receptors: a converging pathway leading to chagasic
vasculopathy,” British Journal of Pharmacology, vol. 165, no. 5,
pp. 1333–1347, 2012.
[36] J. Kaufmann,M. Haasemann, S. Modrow, andW.Mu¨ller-Esterl,
“Structural dissection of the multidomain kininogens. Fine
mapping of the target epitopes of antibodies interfering with
their functional properties,”The Journal of Biological Chemistry,
vol. 268, no. 12, pp. 9079–9091, 1993.
[37] B. Korkmaz, S. Attucci, M. A. Juliano et al., “Measuring
elastase, proteinase 3 and cathepsin G activities at the surface of
human neutrophils with fluorescence resonance energy transfer
substrates,” Nature Protocols, vol. 3, no. 6, pp. 991–1000, 2008.
[38] A. Fukumizu and Y. Tsuda, “Amino acids and peptides. LIII.
Synthesis and biological activities of some pseudo-peptide
analogs of PKSI-527, a plasma kallikrein selective inhibitor: the
importance of the peptide backbone,” Chemical and Pharma-
ceutical Bulletin, vol. 47, no. 8, pp. 1141–1144, 1999.
[39] E. Svensjo¨, “Bradykinin and prostaglandin E1, E2 and F2𝛼-
induced macromolecular leakage in the hamster cheek pouch,”
Prostaglandines and Medicine, vol. 1, no. 5, pp. 397–410, 1978.
[40] E. Svensjo¨, K. E. Andersson, E. Bouskela, F. Z. G. A. Cyrino,
and S. Lindgren, “Effects of two vasodilatory phosphodiesterase
inhibitors on bradykinin-induced permeability increase in the
hamster cheek pouch,” Agents and Actions, vol. 39, no. 1-2, pp.
35–41, 1993.
[41] S. Rosengren, K. Ley, and K.-E. Arfors, “Dextran sulfate
prevents LTB4-induced permeability increase, but not neu-
trophil emigration, in the hamster cheek pouch,”Microvascular
Research, vol. 38, no. 3, pp. 243–254, 1989.
[42] D. C. Ho¨cking, T. J. Ferro, and A. Johnson, “Dextran sul-
fate inhibits PMN-dependent hydrostatic pulmonary edema
induced by tumor necrosis factor,” Journal of Applied Physiology,
vol. 70, no. 3, pp. 1121–1128, 1991.
[43] R. A. Brown, R. Lever, N. A. Jones, and C. P. Page, “Effects of
heparin and relatedmolecules upon neutrophil aggregation and
elastase release in vitro,” British Journal of Pharmacology, vol.
139, no. 4, pp. 845–853, 2003.
[44] K. Ley, M. Cerrito, and K.-E. Arfors, “Sulfated polysaccharides
inhibit leukocyte rolling in rabbitmesentery venules,”American
Journal of Physiology. Heart and Circulatory Physiology, vol. 260,
no. 5, pp. H1667–H1673, 1991.
[45] M. Siebeck, J. C. Cheronis, E. Fink et al., “Dextran sulfate
activates contact system and mediates arterial hypotension via
B2 kinin receptors,” Journal of Applied Physiology, vol. 77, no. 6,
pp. 2675–2680, 1994.
[46] A. Barbasz andA. Kozik, “The assembly and activation of kinin-
forming systems on the surface of human U-937 macrophage-
like cells,” Biological Chemistry, vol. 390, no. 3, pp. 269–275,
2009.
[47] E. del Nery, M. A. Juliano, A. P. C. A. Lima, J. Scharfstein,
and L. Juliano, “ Kininogenase activity by the major cysteinyl
proteinase (cruzipain) from Trypanosoma cruzi,” Journal of
Biological Chemistry, vol. 272, no. 41, pp. 25713–25718, 1997.
[48] A. P. C. A. Lima, P. C. Almeida, I. L. S. Tersariol et al., “Heparan
sulfate modulates kinin release by Trypanosoma cruzi through
the activity of cruzipain,” The Journal of Biological Chemistry,
vol. 277, no. 8, pp. 5875–5881, 2002.
[49] J. Scharfstein, V. Schmitz, V. Morandi et al., “Host cell invasion
byTrypanosoma cruzi is potentiated by activation of bradykinin
B2 receptors,”The Journal of ExperimentalMedicine, vol. 192, no.
9, pp. 1289–1299, 2000.
[50] C. Oschatz, C. Maas, B. Lecher et al., “Mast cells increase vascu-
lar permeability by heparin-initiated bradykinin formation in
vivo,” Immunity, vol. 34, no. 2, pp. 258–268, 2011.
[51] D. Moreno-Sanchez, L. Hernandez-Ruiz, F. A. Ruiz, and R.
Docampo, “Polyphosphate is a novel pro-inflammatory regu-
lator of mast cells and is located in acidocalcisomes,” Journal of
Biological Chemistry, vol. 287, no. 34, pp. 28435–28444, 2012.
[52] G. F. Spa¨th, L. A. Garraway, S. J. Turco, and S. M. Beverley, “The
role(s) of lipophosphoglycan (LPG) in the establishment of
Leishmania major infections in mammalian hosts,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 100, no. 16, pp. 9536–9541, 2003.
[53] C. R. Carter, J. P. Whitcomb, J. A. Campbell, R. M. Mukbel,
andM. A.McDowell, “Complement receptor 3 deficiency influ-
ences lesion progression during Leishmania major infection in
BALB/cMice,” Infection and Immunity, vol. 77, no. 12, pp. 5668–
5675, 2009.
[54] J. L. M. Wanderley and M. A. Barcinski, “Apoptosis and
apoptotic mimicry: the Leishmania connection,” Cellular and
Molecular Life Sciences, vol. 67, no. 10, pp. 1653–1659, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
